596 related items for PubMed ID: 16412833
1. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[Abstract] [Full Text] [Related]
2. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
Karabudak R, Kurne A, Guc D, Sengelen M, Canpinar H, Kansu E.
J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
[Abstract] [Full Text] [Related]
3. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
Yushchenko M, Mäder M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F.
J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
[Abstract] [Full Text] [Related]
4. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X.
Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
[Abstract] [Full Text] [Related]
5. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D.
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[Abstract] [Full Text] [Related]
6. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Bernal F, Elias B, Hartung HP, Kieseier BC.
Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643
[Abstract] [Full Text] [Related]
7. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
8. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP.
Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
[Abstract] [Full Text] [Related]
9. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Benesová Y, Vasku A, Novotná H, Litzman J, Stourac P, Beránek M, Kadanka Z, Bednarík J.
Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
[Abstract] [Full Text] [Related]
10. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
[Abstract] [Full Text] [Related]
11. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E, Tola MR, Dallocchio F, Granieri E, Bellini T.
Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
[Abstract] [Full Text] [Related]
12. Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Sellner J, Greeve I, Leib SL, Mattle HP.
Arch Neurol; 2008 May; 65(5):672-4. PubMed ID: 18474748
[No Abstract] [Full Text] [Related]
13. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE.
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[Abstract] [Full Text] [Related]
14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
15. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
Ichiyama T, Kajimoto M, Suenaga N, Maeba S, Matsubara T, Furukawa S.
J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
[Abstract] [Full Text] [Related]
16. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[Abstract] [Full Text] [Related]
17. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z.
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[Abstract] [Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY.
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[Abstract] [Full Text] [Related]
19. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
Ichiyama T, Siba P, Suarkia D, Takasu T, Miki K, Kira R, Kusuhara K, Hara T, Toyama J, Furukawa S.
J Neurol Sci; 2007 Jan 15; 252(1):45-8. PubMed ID: 17118404
[Abstract] [Full Text] [Related]
20. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
Am Heart J; 2005 Sep 15; 150(3):484-7. PubMed ID: 16169329
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
